| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5369 | V-06-018 | Quorum sensing modulator as a LasR antagonist |
|
| DCC5370 | V-10367 | Non-immunosuppressive immunophilins ligand, demonstrating enhanced neuroregeneration in the peripheral nervous system and CNS |
|
| DCC5371 | V2 Inhibitor 4b | Novel Long Residence Time Superior Inhibitor of the Vasopressin V2 Receptor |
|
| DCC5372 | V30-sp-8 | Novel Mycobacterium Tuberculosis VapC-Activating Stapled Peptide, successfully penetrated Mycobacterium smegmatis cell membranes and exerted bactericidal activity at a minimum inhibitory concentration that inhibited 50% of the isolates (MIC50) < 6.25 μM |
|
| DCC5373 | V4-015 | Novel potent inhibitor of FGFR4 kinase activity |
|
| DCC5374 | Va999024 | Specific inhibitor of tissue Kallikrein>kallikrein |
|
| DCC5375 | Vabicaserin Hydrochloride | Selective 5-HT2C receptor full agonist |
|
| DCC5376 | Vadaclidine | Orally acting antinociceptive muscarinic agonist |
|
| DCC5377 | Valganciclovir | Prodrug of ganciclovir for treatment of cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant |
|
| DCC5378 | Validamine | Natural pseudo-aminosugar |
|
| DCC5379 | Valoluc | Novel prodrug of luciferin to mimic the transport and activation of valacyclovir, , being a robust and functional determinant of VACVase activity |
|
| DCC5380 | Vandetanib Fumarate | Novel selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability |
|
| DCC5381 | Vanillylidenacetone | Novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice |
|
| DCC5382 | Varenicline Dihydrochloride | Partial α4ß2 nicotinic receptor agonist and α7 full agonist |
|
| DCC5383 | Variegatic Acid | Natural inhibitor of β-hexosaminidase release and tumor necrosis factor (TNF)-α secretion from rat basophilic leukemia (RBL 2H3) cells, with IC50 values of 10.4 μM and 16.8 μM, respectively, also inhibiting PKC β1 activity with an IC50 value of 36.2 μM |
|
| DCC5384 | Vb-201 | Novel anticryptosporidial agent, acting as a toll-like receptor-2 (TLR2) antagonist |
|
| DCC5385 | Vb-703 | Novel potent TLR‐4 activation inhibitor, attenuating the expression of fibrosis hallmark genes collagen, fibronectin (FN) and transforming growth factor β (TGF‐β) in kidneys and improved albumin/creatinine ratio with higher efficacy |
|
| DCC5386 | Vbit-12 | Novel potent inhibitor of VDAC1, directly interacting with purified VDAC1 and reducing its channel conductance |
|
| DCC5387 | Vbit-3 | Novel inhibitor of VDAC1 oligomerization and apoptosis |
|
| DCC5388 | Vch-759 | Novel non-nucleoside inhibitor of HCV RNA-dependent polymerase |
|
| DCC5389 | Vchcaγ Inhibitor 40 | Novel selective inhibitor of the γ-class enzyme of bacteria Vibrio cholerae A (VchCAγ) |
|
| DCC5390 | Vd11-4-2 | Novel potent and selective CA IX inhibitor |
|
| DCC5391 | Vd12-09 | Novel potent and selective CA IX inhibitor |
|
| DCC5392 | Vdr Modulator C4 | Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine |
|
| DCC5393 | Vdr Modulator I5 | Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine |
|
| DCC5394 | Vdr Modulator I8 | Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine |
|
| DCC5395 | Ve-465 | Novel Aurora kinase inhibitor |
|
| DCC5396 | Vegfr-in-v | Potent, Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitor |
|
| DCC5397 | Veledimex | Activator for Proprietary Gene Therapy Promoter System |
|
| DCC5398 | Venlafaxine | Serotonin-norepinephrine reuptake inhibitor (SNRI); Antidepressant |
|
